Abstract
BackgroundIncreased serum remnant lipoproteins are supposed to predict cardiovascular disease in addition to increased LDL. A new homogenous assay for remnant lipoprotein-cholesterol (RemL-C) has been developed as an alternative to remnant-like particle-cholesterol (RLP-C), an immunoseparation assay, widely used for the measurement of remnant lipoprotein cholesterol.MethodsWe evaluated the correlations and data validation between the 2 assays in 83 subjects (49 men and 34 women) without diabetes, hypertension and medications for hyperlipidemia, diabetes, and hypertension, and investigated the characteristics of remnant lipoproteins obtained by the two methods (RLP-C and RemL-C) and their relationships with IDL-cholesterol determined by our developed HPLC method.ResultsA positive correlation was significantly found between the two methods (r = 0.853, 95%CI 0.781–0.903, p < 0.0001). Bland & Altman analysis revealed that RemL-C values were likely to be significantly higher than RLP-C values, particularly in samples with high levels of remnant lipoproteins. Several data dissociations between the RemL-C and RLP-C were also observed. The HPLC chromatograms show high concentrations of chylomicron cholesterol in serum samples with RemL-C level < RLP-C level, but high concentrations of IDL-cholesterol in samples with RemL-C level > RLP-C level. RemL-C (r = 0.339, 95%CI 0.152–0.903; p = 0.0005) significantly correlated with IDL-cholesterol, but not RLP-C (r = 0.17, 95%CI -0.047–0.372; p = 0.1237) in all the samples (n = 83).ConclusionThese results suggest that there is generally a significant correlation between RemL-C and RLP-C. However, RemL-C assay is likely to reflect IDL more closely than RLP-C.
Highlights
Increased serum remnant lipoproteins are supposed to predict cardiovascular disease in addition to increased low-density lipoprotein (LDL)
Many clinical studies have demonstrated that RLPC is a risk factor for cardiovascular disease, and serum remnant-like particle-cholesterol (RLP-C) levels are higher in patients with coronary artery disease, diabetes, and metabolic syndrome than in healthy subjects [2,4,11]
We evaluated the correlations and data validation between the 2 assays (RLP-C and remnant lipoproteincholesterol (RemL-C)) in subjects without diabetes, hypertension and medications for hyperlipidemia, diabetes, and hypertension, and investigated the characteristics of remnant lipoproteins obtained by the two assays and their relationships with IDL-cholesterol determined quantitatively by our high performance liquid chromatography (HPLC) method
Summary
Increased serum remnant lipoproteins are supposed to predict cardiovascular disease in addition to increased LDL. Hypertriglyceridemia is a heterogeneous disorder of lipoprotein metabolism with a less definite association to atherosclerosis risk than hypercholesterolemia or increased low-density lipoprotein (LDL)-cholesterol [1]. Patients with moderate hypertriglyceridemia such as familial combined hyperlipidemia, diabetic dyslipidemia, or metabolic syndrome more often develop premature atherosclerotic diseases, because smaller-sized triglyceride (TG)-rich lipoproteins such as chylomicron remnants and very-low-density lipoprotein (VLDL) remnants penetrate the arterial intima from plasma, than larger-sized chylomicrons [1,2,3,4,5,6]. Many clinical studies have demonstrated that RLPC is a risk factor for cardiovascular disease, and serum RLP-C levels are higher in patients with coronary artery disease, diabetes, and metabolic syndrome than in healthy subjects [2,4,11]. RLP-C measurement can be performed without an ultracentrifugation, but it takes some time and is not able to be run on an autoanalyzer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
